Why Moderna Stock Plunged Today

Shares of Moderna (NASDAQ: MRNA) fell 12% on Wednesday after a court ruling placed a portion of the biotech's blockbuster COVID-19 vaccine proceeds at risk.

A U.S. Court of Appeals for the Federal Circuit panel affirmed a previous ruling by the U.S. Patent and Trademark Office's Patent Trial and Appeal Board. The decision blocked Moderna's attempts to invalidate two of Arbutus Biopharma's (NASDAQ: ABUS) patents on its lipid nanoparticle (LNP) drug-delivery technology.

Moderna uses LNP to deliver its messenger RNA (mRNA) COVID-19 vaccine safely and effectively into patients. 

Continue reading

Source Fool.com